| Biomarker ID | 600 |
| PMID | 21367627 |
| Year | 2011 |
| Biomarker | matrix metalloproteinase-9 (MMP-9) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway Includes:- Syndecan 1 pathway,Gastrin pathway,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,TWEAK signaling pathway, Endochondral ossification |
| Experiment | BPH Vs Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 148 CaP patients who underwent radical prostatectomy for clinically localized disease and 10 samples of benign prostatic hyperplasia (BPH) were chosen for the study. 67 cases were T2, and 81 were T3– 4. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.004 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MMP9 |